FiercePharma

The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome

The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome The only transdermal dopamine agonist*1 system, which helps ...
FierceBiotech

Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome

ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has ...
FierceBiotech

Press Release: FDA Approves Schwarz Pharma's Neupro for the Treatment of Early-Stage Parkinson's Disease in the U.S.

FDA Approves Schwarz Pharma's Neupro for the Treatment of Early-Stage Parkinson's Disease in the U.S. MONHEIM, Germany, May 10 -- SCHWARZ PHARMA announced today that the U.S. Food and Drug ...
FiercePharma

Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome

Neupro® (Rotigotine Transdermal System) is approved to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary restless legs syndrome ...
Healthline

Neupro Interactions: Alcohol, Medications, and Others

Neupro (rotigotine) is a prescription skin patch used to treat Parkinson’s disease and restless legs syndrome in adults. Neupro has interactions with other drugs and alcohol. For example, it can ...

Shilpa Medicare receives initial authorization from Europe for Rotigotine Transdermal Patch

Shilpa Medicare has received the Initial Authorization from Europe, recommending the grant of the final Marketing Authorization for Shilpa Medicare's prescription product, Rotigotine 1, 2, 3, 4, 6, 8 ...